Overexpressed Exogenous IL-4 And IL-10 Paradoxically Regulate Allogenic T-Cell and Cardiac Myocytes Apoptosis Through FAS/FASL Pathway
Authors:
- 15 February 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 85 (3) , 437-446
Abstract
Background. The authors' previous study has shown that liposome-mediated ex vivo intracoronary interleukin (IL)-4 and IL-10 combined gene therapy suppressed the allo-immune responses and prolonged the cardiac allograft survival by 15 folds. However, the mechanism for promoting long-term allograft survival remains unknown. Methods. This study tested the hypothesis that this combined cytokine gene targeting may promote alloreactive T-cell apoptosis or prevent apoptosis of cardiac allograft myocytes through Fas/Fas ligand (FasL) pathway. A rabbit functional cervical heterotopic heart transplantation model was used, and plasmid human recombinant IL-4 and IL-10 gene complexed with cationic liposome (GAP/DLRIE) was delivered into cardiac allografts by intracoronary infusion ex vivo. Results. This liposome-mediated IL-4 and IL-10 combined gene therapy significantly increased apoptotic T cells detected by TUNEL staining. The caspase-8 or caspase-3 expressing T cells were also significantly increased. The Fas+ apoptotic T cells dominated in the population of apoptotic CD4+ T cells, but FasL+ CD4+ T-cell population was less effected in the combined gene therapy group. The effect of combined gene therapy on the infiltrative Fas+ CD8+ T-cell population is much less than that on Fas+ CD4+ cells, and there was almost no effect on the FasL+ CD8+ T-cell population. Furthermore, localized IL-4 and IL-10 combined gene therapy protected cardiac allograft myocytes by down-regulating its FasL expression, but not Fas. Conclusions. These results suggest that this combined gene targeting strategy which induced localized overexpression of exogenous IL-4 and IL-10 may promote alloreactive T-cell apoptosis and prevent myocytes apoptosis through Fas/FasL cell surface interaction, therefore inducing cardiac allograft tolerance.Keywords
This publication has 45 references indexed in Scilit:
- Administration of plasmids expressing interleukin‐4 and interleukin‐10 causes BALB/c mice to induce a T helper 2‐type response despite the expected T helper 1‐type response with a low‐dose infection ofLeishmania majorImmunology, 2002
- IL-4 Suppression of In Vivo T Cell Activation and Antibody ProductionThe Journal of Immunology, 2000
- COMBINED THERAPY WITH INTERLEUKIN-4 AND INTERLEUKIN-10 INHIBITS AUTOIMMUNE DIABETES RECURRENCE IN SYNGENEIC ISLET-TRANSPLANTED NONOBESE DIABETIC MICE ANALYSIS OF CYTOKINE MRNA EXPRESSION IN THE GRAFTTransplantation, 1995
- Interleukin-10 inhibits interleukin-8 production in human neutrophilsBlood, 1994
- Mechanism of suppression of nitric oxide synthase expression by interleukin-4 in primary mouse macrophagesJournal of Leukocyte Biology, 1994
- Interleukin‐4 and interleukin‐10 synergize to inhibit cell‐mediated immunity in vivoEuropean Journal of Immunology, 1993
- Macrophage deactivation by interleukin 10.Journal of Experimental Medicine, 1991
- Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.Journal of Experimental Medicine, 1991
- Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human monocytesBlood, 1990
- Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2.Proceedings of the National Academy of Sciences, 1989